PKS Holdings Limited (ASX: PKS), an Australian healthcare company, has executed an agreement with Abbott Laboratories to improve and extend the Abbott Software License and Distribution Agreement.
Key highlights of the improved commercial terms:
- The addition of a new volume based-license mechanism which measures the number of patient episodes and charges additional recurring licensing based on the total customer episodes;
- The growth in the commercial licensing pricing to address CPI since inception (April 2016);
- Extension of the Term to 30 April 2022, with an automatic 2-year renewal period, subject to 6-month prior notice.
At AEST 12:59PM, the stock was trading at $0.175 per share, up by 2.9% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.